Spondyloarthritis & psoriatic arthritis
Secukinumab improves physical function and quality of life and inhibits structural damage in patients with psoriatic arthritis (PsA) with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study
Authors' conclusion
Sustained LDA/REM was associated with improvements in physical function, QoL and inhibition of structural damage progression.
Study context
- Population
- Patients with active PsA in the FUTURE 5 study, categorised by low disease activity (LDA) (MDA/DAPSA LDA+remission (REM)) or REM (very LDA/DAPSA REM): not achieved, achieved once, or sustained ≥3 times up to week 104
- Participants
- 996 patients
- Comparison
- Sustained LDA/REM vs LDA/REM achieved once or not at all in secukinumab-treated patients
- Secukinumab 300 mgn = 222
- Secukinumab 150 mg loadingn = 220
- Secukinumab 150 mg non-loadingn = 222
- Placebon = 332reference
- Primary endpoint
- Improvements in HAQ-DI and SF-36 Physical Component Summary Score, proportion of non-radiographic progressors and predictors of sustained LDA response
- Follow-up
- Up to week 104
Methodological detailsdouble-blind, placebo-controlled, parallel-group, phase 3
- Double-blind
- Placebo-controlled
- Parallel-group
- Phase 3
Primary result
As reported in the abstract
Sustained LDA
48%-81%
Sustained REM
19%-36%
Original publication
Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study. RMD Open. Published 24 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →